Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD45CU)

• Drug Name: 2-Methyl-2,4-Pentanediol Drug Info
• Synonyms: 2-METHYL-2,4-PENTANEDIOL; 107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 7870
  ChEBI ID: CHEBI:62995
  CAS Number: CAS 107-41-5
  TTD Drug ID: DMD45CU

Molecule-Related Drug Atlas

Drug(s) Targeting Presynaptic density protein 95 (DLG4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tat-NR2B9c	DMD6AUX	Cerebrovascular ischaemia	8B1Z	Phase 3	[2]
Guanosine-5'-Monophosphate	DM3SLZK	Discovery agent	N.A.	Investigative	[1]
KSG-YEKLSSIESDV	DMPLFRC	Discovery agent	N.A.	Investigative	[3]
N-(3,4-Difluorophenyl)propyl-ETAV	DMF2D4O	Discovery agent	N.A.	Investigative	[3]
N-Propyl-ETAV	DMUTDNV	Discovery agent	N.A.	Investigative	[3]
N-Phenylethyl-ETAV	DM1VSO9	Discovery agent	N.A.	Investigative	[3]
N-Cyclohexylmethyl-ETAV	DMIC8Z6	Discovery agent	N.A.	Investigative	[3]
FETAV	DMO1N2T	Discovery agent	N.A.	Investigative	[3]
N-Butyl-ETAV	DMY3HEF	Discovery agent	N.A.	Investigative	[3]
N-Methyl-ETAV	DMP1EF6	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Nitric-oxide synthase endothelial (NOS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tilarginine acetate	DMZBGI8	Myocardial infarction	BA41-BA43	Phase 3	[4]
L-NAME	DM01SR6	Hypertension	BA00-BA04	Phase 2	[5]
ACCLAIM	DM0FGDO	Angina pectoris	BA40	Phase 2	[6]
VAS-203	DMKU93J	Brain injury	NA07.Z	Phase 2	[7]
MTR105	DMT0K4F	Hypotension	BA20-BA21	Phase 2	[8]
Autologous cell based gene therapy	DMQA1VT	Pulmonary hypertension	BB01	Phase 1	[9]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[10]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[11]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[12]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[13]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[14]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[15]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[16]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[17]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[18]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[19]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[20]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[21]

Drug(s) Targeting Bacterial Glucosamine-6-phosphate synthase (Bact glmS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucose-6-Phosphate	DMKY1L4	N. A.	N. A.	Phase 1	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Glucose-6-Phosphate	DMR0EVN	Discovery agent	N.A.	Investigative	[1]
Glutamine Hydroxamate	DMT7K0U	Discovery agent	N.A.	Investigative	[1]
2-Deoxy-2-Amino Glucitol-6-Phosphate	DMBMK4T	Discovery agent	N.A.	Investigative	[1]
Glucosamine 6-Phosphate	DMY590Q	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Heat shock protein 90 alpha (HSP90A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cromoglicate	DM74LZK	Asthma	CA23	Approved	[22]
Amlexanox	DM0DQM5	Respiratory tract inflammation	CA07	Approved	[22]
NVP-AUY922	DMTYXQF	Multiple myeloma	2A83	Phase 2	[23]
BIIB-021	DMPAJ41	Breast cancer	2C60-2C65	Phase 2	[24]
KW-2478	DMJGL72	Solid tumour/cancer	2A00-2F9Z	Phase 2	[25]
VER 50589	DMFLZPC	Breast cancer	2C60-2C65	Phase 2	[23]
Tanespimycin	DMNLQHK	Breast cancer	2C60-2C65	Phase 2	[26]
Efungumab	DMBHP56	Breast cancer	2C60-2C65	Phase 2	[27]
SNX-5422	DMIU0VP	Haematological malignancy	2B33.Y	Phase 1/2	[28]
PU3	DMJO0BP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[23]

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[1]
Miltefosine	DMND304	Chronic urticaria		Approved	[29]
Clocortolone	DM9ZMQH	Exanthem		Approved	[30]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[31]
Diflorasone	DMI9PRJ	Exanthem		Approved	[32]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[33]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[34]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[35]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[36]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[37]

Drug(s) Targeting Staphylococcus Beta-lactamase (Stap-coc blaZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazobactam	DM3XNUI	Appendicitis	DB10	Approved	[38]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[39]
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[40]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[41]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[42]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[43]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[44]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[45]
ME-1071	DMEMQ5J	Bacterial infection	1A00-1C4Z	Phase 1	[46]
OP-0595	DMECVP9	Bacterial infection	1A00-1C4Z	Phase 1	[47]

Drug(s) Targeting Calmodulin (CALM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halofantrine	DMOMK1V	Malaria	1F40-1F45	Approved	[48]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[49]
Aprindine	DMBXWU8	Cardiac arrhythmias	BC9Z	Approved	[50]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[11]
Cacodylate Ion	DMK4XLD	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2-Propanol	DMHM5GJ	Discovery agent	N.A.	Investigative	[1]
N-Trimethyllysine	DMZQXLS	Discovery agent	N.A.	Investigative	[1]
Calmidazolium	DM5ZTJL	Huntington disease	8A01.10	Investigative	[51]

Drug(s) Targeting Dihydrodiol dehydrogenase type I (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[52]
ASP-9521	DM8V0UL	Prostate cancer	2C82.0	Phase 1/2	[53]
N-(benzimidazole/indole) benzoic acid derivative 2	DMOPUFM	N. A.	N. A.	Patented	[54]
N-(phenylamino)-benzoate derivative 1	DMNIWVG	N. A.	N. A.	Patented	[54]
Indomethacin analog 3	DM53JXE	N. A.	N. A.	Patented	[54]
Indomethacin analog 2	DMKFPJ7	N. A.	N. A.	Patented	[54]
Beta-naphthylacetic acids derivative 1	DM5KTDY	N. A.	N. A.	Patented	[54]
Indomethacin analog 1	DM3E5V6	N. A.	N. A.	Patented	[54]
N-(naphthylamino)-benzoate derivative 1	DM310ES	N. A.	N. A.	Patented	[54]
N-(benzimidazolylcarbonyl)-piperidine derivative 1	DM541QW	N. A.	N. A.	Patented	[54]

Drug(s) Targeting CTP synthase (CTPS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyclopentenylcytosine	DMAWVTX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[55]
Acivicin	DMPQZ80	N. A.	N. A.	Discontinued in Phase 3	[56]
Cyclopentylcytosine	DM4KZ1W	Discovery agent	N.A.	Investigative	[55]
Carbodine	DMA3FZR	Discovery agent	N.A.	Investigative	[57]
Cylopentenyl cytosine	DMQWLIC	Discovery agent	N.A.	Investigative	[58]

Drug(s) Targeting Placenta growth factor (PlGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[59]
RO-5323441	DMUB3OY	Solid tumour/cancer	2A00-2F9Z	Phase 2	[60]
TB-403	DMDPBMH	Glioblastoma of brain	2A00.00	Phase 2	[61]
SFLT-01	DMD2GKF	Macular degeneration	9B78.3	Phase 1	[62]
R7334	DMVA186	Macular degeneration	9B78.3	Phase 1	[63]

Drug(s) Targeting PTPN1 messenger RNA (PTPN1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[64]
TRYPAN BLUE	DM4NTMO	Ophthalmic surgery injury	PK97	Approved	[65]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[66]
ISIS 113715	DMUPD4G	Type-2 diabetes	5A11	Phase 2	[67]
ISIS-PTP1Brx	DMJGVXT	Type-2 diabetes	5A11	Phase 2	[68]
ERTIPROTAFIB	DMJXEV7	Type-2 diabetes	5A11	Terminated	[69]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[1]
1,2-NAPHTHOQUINONE	DMYXELH	Discovery agent	N.A.	Investigative	[70]

Drug(s) Targeting Phosphopantetheine adenylyltransferase (PPAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PTX-007011	DM89RT7	Bacterial infection	1A00-1C4Z	Terminated	[71]
Coenzyme A	DM1I8LU	Discovery agent	N.A.	Investigative	[1]
4'-Phosphopantetheine	DMJ0A4Z	Discovery agent	N.A.	Investigative	[1]
Dephospho Coenzyme A	DMGHM1L	Discovery agent	N.A.	Investigative	[72]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Glucosamine-6-phosphate synthase (Bact glmS)	TTC67I0	GLMS_ECOLI	Inhibitor	[1]
Calmodulin (CALM)	TTV3NH6	CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN	Inhibitor	[1]
CTP synthase (CTPS1)	TTN12BZ	PYRG1_HUMAN	Inhibitor	[1]
Dihydrodiol dehydrogenase type I (AKR1C3)	TT5ZWB6	AK1C3_HUMAN	Inhibitor	[1]
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[1]
Nitric-oxide synthase endothelial (NOS3)	TTCM4B3	NOS3_HUMAN	Inhibitor	[1]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[1]
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[1]
Phosphopantetheine adenylyltransferase (PPAT)	TT4YO0Z	COASY_HUMAN	Inhibitor	[1]
Placenta growth factor (PlGF)	TT48I1Y	PLGF_HUMAN	Inhibitor	[1]
Presynaptic density protein 95 (DLG4)	TT9PB26	DLG4_HUMAN	Inhibitor	[1]
PTPN1 messenger RNA (PTPN1 mRNA)	TTELIN2	PTN1_HUMAN	Inhibitor	[1]
Staphylococcus Beta-lactamase (Stap-coc blaZ)	TTHI19T	BLAC_STAAU	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7.
• [3] Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
• [4] Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
• [5] Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
• [6] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [7] Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
• [8] Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
• [9] Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
• [10] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [11] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [12] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [13] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [14] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [15] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [16] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [17] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [18] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [19] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [20] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [21] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [22] Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
• [23] Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
• [24] BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
• [25] Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
• [26] Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
• [27] Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
• [28] SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
• [29] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [30] Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
• [31] Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
• [32] Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
• [33] Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
• [34] Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
• [35] Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
• [36] Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
• [37] A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
• [38] Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
• [39] A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
• [40] NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
• [41] Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
• [42] Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
• [43] Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
• [44] Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
• [45] WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
• [46] Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
• [47] OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
• [48] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [49] Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
• [50] Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
• [51] Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
• [52] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [53] Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
• [54] Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.
• [55] Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
• [56] Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Sep;41(9 Pt 1):3419-23.
• [57] Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase. Mol Pharmacol. 1987 Aug;32(1):286-92.
• [58] Comments on: cylopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy. A.C. Verschuur et al. Eur J Cancer 2000, 36, 627-635. Eur J Cancer. 2001 Jan;37(2):290.
• [59] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [60] RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
• [61] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [62] sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
• [63] Clinical pipeline report, company report or official report of Roche (2009).
• [64] Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
• [65] Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
• [66] Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
• [67] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [68] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [69] 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
• [70] Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1941-6.
• [71] NME DIGEST. Drug News & Perspect 2002, 15(8):519, ISSN 0214-0934.
• [72] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.